Top 10 potential targets (EP300, EGFR, TP53, RPS27A, MYC, HSP90AA1, UBC, AKT1, GAPDH, HSPA8) of active compounds from Nux vomica were predicted to be associated with MG treatment. This evidence concerns the gene EGFR and myasthenia gravis.